Thomas Jefferson University

Jefferson Digital Commons
Department of Medicine Faculty Papers

Department of Medicine

1-1-2010

Early detection of response to hydroxyurea therapy in patients
with sickle cell anemia.
Samir K. Ballas
Cardeza Foundation for Hematologic Research, Department of Medicine, Jefferson Medical College,
Thomas Jefferson University

William F. McCarthy
Maryland Medical Research Institute, Baltimore, MD

Nan Guo
Maryland Medical Research Institute, Baltimore, MD

Carlo Brugnara
The Children’s Hospital, Boston, MA

Gail Kling

Follow this and additional works at: https://jdc.jefferson.edu/medfp
Siemens Healthcare Diagnostics Inc., Tarrytown, NY
Part of the Medical Genetics Commons

Let
us know how access to this document benefits you
See next page for additional authors
Recommended Citation
Ballas, Samir K.; McCarthy, William F.; Guo, Nan; Brugnara, Carlo; Kling, Gail; Bauserman, Robert
L.; and Waclawiw, Myron A., "Early detection of response to hydroxyurea therapy in patients with
sickle cell anemia." (2010). Department of Medicine Faculty Papers. Paper 49.
https://jdc.jefferson.edu/medfp/49
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Department of Medicine Faculty Papers by an authorized administrator of the Jefferson
Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Authors
Samir K. Ballas, William F. McCarthy, Nan Guo, Carlo Brugnara, Gail Kling, Robert L. Bauserman, and Myron
A. Waclawiw

This article is available at Jefferson Digital Commons: https://jdc.jefferson.edu/medfp/49

As submitted to:
Hemoglobin
And later published as:
“Early detection of response to
hydroxyurea therapy in patients with
sickle cell anemia”
Volume 34, Issue 5, October 2010,
Pages 424-429
DOI: 10.3109/03630269.2010.513638
Samir K. Ballas1, William F. McCarthy2, Nan Guo2, Carlo Brugnara3, Gail
Kling4, Robert L. Bauserman2, Myron A.Waclawiw5
1

Cardeza Foundation for Hematologic Research, Department of Medicine,
Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA
USA, 2 Maryland Medical Research Institute, Baltimore, MD USA, 3 The
Children’s Hospital, Boston, MA, USA, 4 Siemens Healthcare Diagnostics
Inc., Tarrytown, NY USA, 5 National Heart, Lung and Blood Institute,
Bethesda, Maryland, USA

Corresponding author: Samir K. Ballas MD, FACP, Cardeza
Foundation, Department of Medicine, Jefferson Medical College,
Thomas Jefferson University,1015 walnut Street, Philadelphia, PA
19107, Phone: 215-955-8485, Fax: 856-795- 0809, E-mail:
samir.ballas@jefferson.edu
Shortened title: Early signs of response to hydroxyurea

Text word count: 1099
Abstract word count: 148

Abstract
Red blood cells and reticulocyte parameters were determined on peripheral blood from a
subset of patients enrolled in the Multicenter Study of Hydroxyuea in sickle cell anemia.
Multiple blood samples were obtained every two weeks. Cellular indices were measured
by flow cytometry. Generalized linear models were used to determine the relationship
between the longitudinal trajectories of red blood cell and reticulocyte indices and
hydroxyurea usage. There was a significant relationship between hydroxyurea usage and
most of the red blood cell and reticulocyte indices. Hydroxyurea produced higher value
trajectories than those generated by placebo usage for the hemoglobin content of both
the red blood cells and reticulocytes and for the mean corpuscular volume of

reticulocytes. These changes were first detected 10 weeks after starting hydroxyurea and
before the increase in hemoglobin F levels. The data suggest that subtle and early
markers of response to hydroxyurea reside in the hemogram.
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Introduction
The salutary effects of hydroxyurea (HU) in sickle cell anemia (SS) include decreased
frequency of painful crises, decreased incidence of acute chest syndrome, decreased
blood transfusion, and decreased mortality and morbidity (1-5). Markers of the response
to HU include increased Hb F level, macrocytosis, improved RBC survival and
deformability, and decreased WBC count (!-7). In this study we report markers of early
response to HU by using generalized linear mixed models (GLM) to determine the
relationship between HU usage and the longitudinal trajectories of RBC indices and the
corresponding longitudinal trajectories of reticulocytes indices.

Methods
RBC and reticulocyte parameters were determined on peripheral blood from selected
patients enrolled in the placebo (PL) controlled double blind multicenter study of
hydroxyuea (MSH) in SS. The study cohort for this analysis consisted of 21 patients from
the Thomas Jefferson University, Cardeza Foundation for Hematologic Research (10 HU
subjects, 11 PL subjects). Multiple blood samples were obtained during enrollment in the
study at a rate of about once every two weeks. The mean weeks of follow-up from
enrollment date was 86.6 weeks (range 10-172 weeks). The RBC/PLT channel of the
Siemens H*3 RTX (H*3) hematology analyzer measures the laser light scattered at 2
different angles by red cells which have been isovolumetrically sphered. Using the Mie
theory of light scatter the low angle (2-3o) light intensity directly measures RBC volume
(MCV, femtoliters) and the high angle (5-15 o) light intensity directly measures refractive
index which is a linear function of red cell hemoglobin concentration (CHCM, cell
hemoglobin concentration mean, grams per deciliter). The Reticulocyte channel reagent
also isovolumetrically spheres as well as selectively staining the reticulocytes with the
nucleic acid-binding dye Oxazine 750. Using the same laser optics and principles as the
RBC/PLT channel, reticulocyte volume (MCVr, femtoliters) and reticulocyte hemoglobin
concentration (CHCMr, grams per decilter) are directly measured. An additional detector
measures laser light absorption by the Oxazine 750 dye to separate the reticulocytes from
the mature red cells. The RBC/PLT channel measures the mean hemoglobin content of
the red cells (CH) and the reticulocyte channel measures the mean hemoglobin content of
the reticulocytes (CHr) by multiplying the volume and the cell hemoglobin concentration

mean. RBC and Reticulocyte indices were measured on a Siemens H*3 RTX (H*3)
hematology analyzer. Laser light scattering was used to quantify cell volume, Hb
concentration, and the light absorbance of cells stained with oxazine 750 to detect
reticulocytes and distinguish them from mature cells. A total of 20,000 cells were
counted for each sample. After the volume (V) and Hb concentration (HC) of individual
mature RBC and reticulocytes were measured, the Hb content (CH) of individual cells
was calculated (8).
Generalized linear mixed models (GLM) were used to determine the relationship between
the longitudinal trajectories of RBC and reticulocyte indices and HU usage (9-12). A
first-order autoregressive structure was used (1). Information criteria [Akaike Information
Criterion (AIC)] (13), Akaike Information Criterion, Small Sample Size Corrected
Version (AICC) (14) and the Bayesian Information Criterion (BIC) (15) were used to
compare and determine which GLM provided better insight into the relationship between
the longitudinal trajectories of RBC and reticulocyte indices and HU usage. The
information criteria are all in “smaller-is-better” form. Since the GLM considered
longitudinal data,the time at which the longitudinal trajectories were influenced by HU
usage could also be determined. PROC MIXED (SAS 9.1) was used for the GLM
analyses. Statistical significance was defined as a 2-sided p-value <.05.

Results

The mean weeks (wks) of follow-up from study enrollment date was 86.6 wks (standard
deviation (sd)=38.84 wks; max=172 wks, median=84 wks, min=10 wks). The mean age
of this patient cohort at the start of follow-up was 29.0 years (SD =4 .77 years; max=37
years, median=30 years, min=19 years). There were 13 males (61.9%) and 8 females
(38.1%).

Goodness-of-fit criteria for the GLM indicated that the RBC indices modeled more
precisely than those of reticulocytes. However, both the RBC indices and reticulocytes
provided useful information regarding the relationship between their longitudinal
trajectories and HU usage (Table 1).

There was a significant relationship between HU usage and the following longitudinal
trajectories: mean cell hemoglobin (CH) (p<.0001), reticulocyte mean cell hemoglobin
(CHr) (p<.0001); Cell hemoglobin concentration mean (CHCM) (p=.0394); Reticulocyte
mean cell volume (MCVr) (p=.0019); hemoglobin distribution width (HDW) (p=.0003)
and red blood cell volume distribution width (RDW) (p=.0008). HU usage produced
higher value trajectories than those generated by placebo usage for the following: CH,
CHr; and MCVr (Fig. 1). These changes were first detected 10 weeks after starting HU
and before the increase in Hb F levels.

Discussion
Although HU has been proven to have salutary effects in patients with SS (1-3) its
utilization continues to suffer from two major drawbacks. These include its
underutilization (16) and the fact that at least 25% of patients who take it are nonresponders to its use (1, 2). These two drawbacks seem to re-enforce each other. Thus
some patients may be falsely labeled as non-responders if no effect on frequency of
painful crises and/or no increase in the level of Hb F is seen within 2-3 months after
starting HU at a dose of 10-15 mg/k/day. The reason why some patients do not respond to
HU is unknown. One possibility is that it fails to recruit dormant bone marrow fetal stem
cells that are capable to produce fetal Hb. Moreover, it usually takes at least six months
of therapy with HU before an increase in Hb F is seen (7). Thus an early sign of a
response-in-progress to HU therapy is important information for the provider who is
monitoring the the clinical and hematological data of patients after the initiation of
therapy with HU.
In this study we report markers of early response to HU by using generalized linear
mixed models (GLM) to determine the relationship between HU usage and the
longitudinal trajectories of RBC parameters and the corresponding longitudinal
trajectories of reticulocytes parameters. Specifically HU therapy showed significant
changes in the Hb content (CHr) and cell volume of reticulocyte (MCVr) compared to
placebo within 10 weeks after starting HU indicating an early sign of response to therapy.

Thus the sequence of signs of response to HU include increase in reticulocyte indices
(CHr and MCVr) within 10 weeks after therapy followed by increase in RBC indices and
a later increase (up to six months) in Hb F level.

Conclusion

Together the data suggest that subtle and early markers of response to HU reside in the
hemogram. This is a fast, simple and inexpensive methodology provided the lab in
question has the capability to determine the indices of both reticulocytes and RBC.
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Legend to Figure 1

Time trends in MCV and MCVr by treatment assignment

